These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 29705704

  • 21. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.
    Xia P, Zhang H, Xu K, Jiang X, Gao M, Wang G, Liu Y, Yao Y, Chen X, Ma W, Zhang Z, Yuan Y.
    Cell Death Dis; 2021 Jul 09; 12(7):691. PubMed ID: 34244479
    [Abstract] [Full Text] [Related]

  • 22. FOXM1 Is a Novel Molecular Target of AFP-Positive Hepatocellular Carcinoma Abrogated by Proteasome Inhibition.
    Li R, Okada H, Yamashita T, Nio K, Chen H, Li Y, Shimakami T, Takatori H, Arai K, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S.
    Int J Mol Sci; 2022 Jul 27; 23(15):. PubMed ID: 35955438
    [Abstract] [Full Text] [Related]

  • 23. TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1-Forkhead box M1 regulation loop.
    Park TJ, Kim JY, Oh SP, Kang SY, Kim BW, Wang HJ, Song KY, Kim HC, Lim IK.
    Hepatology; 2008 May 27; 47(5):1533-43. PubMed ID: 18393292
    [Abstract] [Full Text] [Related]

  • 24. Comprehensive clinicopathological significance and putative transcriptional mechanisms of Forkhead box M1 factor in hepatocellular carcinoma.
    Wu HY, Luo LF, Wei F, Jiang HM.
    World J Surg Oncol; 2023 Nov 25; 21(1):366. PubMed ID: 38001498
    [Abstract] [Full Text] [Related]

  • 25. Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation though targeting FOXM1.
    Huang X, Qin J, Lu S.
    Int J Clin Exp Pathol; 2015 Nov 25; 8(2):1515-24. PubMed ID: 25973036
    [Abstract] [Full Text] [Related]

  • 26. Molecular mechanism of Forkhead box M1 inhibition by thiostrepton in breast cancer cells.
    Kongsema M, Wongkhieo S, Khongkow M, Lam EW, Boonnoy P, Vongsangnak W, Wong-Ekkabut J.
    Oncol Rep; 2019 Sep 25; 42(3):953-962. PubMed ID: 31322278
    [Abstract] [Full Text] [Related]

  • 27. Opposing Roles of the Forkhead Box Factors FoxM1 and FoxA2 in Liver Cancer.
    Chand V, Pandey A, Kopanja D, Guzman G, Raychaudhuri P.
    Mol Cancer Res; 2019 May 25; 17(5):1063-1074. PubMed ID: 30814128
    [Abstract] [Full Text] [Related]

  • 28. Long noncoding RNA SLC2A1-AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3/FOXM1/GLUT1 pathway.
    Shang R, Wang M, Dai B, Du J, Wang J, Liu Z, Qu S, Yang X, Liu J, Xia C, Wang L, Wang D, Li Y.
    Mol Oncol; 2020 Jun 25; 14(6):1381-1396. PubMed ID: 32174012
    [Abstract] [Full Text] [Related]

  • 29. XTP8 promotes hepatocellular carcinoma growth by forming a positive feedback loop with FOXM1 oncogene.
    Han M, Lu H, Han K, Yuan X, Liu S, Wang Y, Zhao J, Liang P, Cheng J.
    Biochem Biophys Res Commun; 2019 Jul 30; 515(3):455-461. PubMed ID: 31164201
    [Abstract] [Full Text] [Related]

  • 30. Activation of AKT/AP1/FoxM1 signaling confers sorafenib resistance to liver cancer cells.
    Yan D, Yan X, Dai X, Chen L, Sun L, Li T, He F, Lian J, Cai W.
    Oncol Rep; 2019 Aug 30; 42(2):785-796. PubMed ID: 31233189
    [Abstract] [Full Text] [Related]

  • 31. FOXM1 augments sorafenib resistance and promotes progression of hepatocellular carcinoma by epigenetically activating KIF23 expression.
    Zhu C, Guo H, Ma Z, Shi S, Zhao X, Zhai D, Zhou X, Jiang P, Xu Q, Cai J.
    Biochem Biophys Res Commun; 2023 May 14; 656():1-9. PubMed ID: 36940637
    [Abstract] [Full Text] [Related]

  • 32. LncRNA MFI2-AS1 promotes HCC progression and metastasis by acting as a competing endogenous RNA of miR-134 to upregulate FOXM1 expression.
    Wei Y, Wang Z, Zong Y, Deng D, Chen P, Lu J.
    Biomed Pharmacother; 2020 May 14; 125():109890. PubMed ID: 32106369
    [Abstract] [Full Text] [Related]

  • 33. Knockdown of FoxM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro.
    Wu QF, Liu C, Tai MH, Liu D, Lei L, Wang RT, Tian M, Lü Y.
    Acta Pharmacol Sin; 2010 Mar 14; 31(3):361-6. PubMed ID: 20154714
    [Abstract] [Full Text] [Related]

  • 34. PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of β-Catenin signaling in hepatocellular carcinoma.
    Yang YF, Pan YH, Cao Y, Fu J, Yang X, Zhang MF, Tian QH.
    Oncotarget; 2017 Jul 18; 8(29):47195-47205. PubMed ID: 28525379
    [Abstract] [Full Text] [Related]

  • 35. FoxM1 promotes epithelial-mesenchymal transition of hepatocellular carcinoma by targeting Snai1.
    Yu CP, Yu S, Shi L, Wang S, Li ZX, Wang YH, Sun CJ, Liang J.
    Mol Med Rep; 2017 Oct 18; 16(4):5181-5188. PubMed ID: 28849004
    [Abstract] [Full Text] [Related]

  • 36. Negative regulation of transcription factor FoxM1 by p53 enhances oxaliplatin-induced senescence in hepatocellular carcinoma.
    Qu K, Xu X, Liu C, Wu Q, Wei J, Meng F, Zhou L, Wang Z, Lei L, Liu P.
    Cancer Lett; 2013 Apr 30; 331(1):105-14. PubMed ID: 23262037
    [Abstract] [Full Text] [Related]

  • 37. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
    Wei JC, Meng FD, Qu K, Wang ZX, Wu QF, Zhang LQ, Pang Q, Liu C.
    Acta Pharmacol Sin; 2015 Feb 30; 36(2):241-51. PubMed ID: 25557114
    [Abstract] [Full Text] [Related]

  • 38. Isovitexin reduces carcinogenicity and stemness in hepatic carcinoma stem-like cells by modulating MnSOD and FoxM1.
    Cao X, Liu L, Yuan Q, Li X, Cui Y, Ren K, Zou C, Chen A, Xu C, Qiu Y, Quan M, Zhang J, Cao J, Chen X.
    J Exp Clin Cancer Res; 2019 Jun 17; 38(1):264. PubMed ID: 31208440
    [Abstract] [Full Text] [Related]

  • 39. USP39 promotes the growth of human hepatocellular carcinoma in vitro and in vivo.
    Yuan X, Sun X, Shi X, Jiang C, Yu D, Zhang W, Guan W, Zhou J, Wu Y, Qiu Y, Ding Y.
    Oncol Rep; 2015 Aug 17; 34(2):823-32. PubMed ID: 26081192
    [Abstract] [Full Text] [Related]

  • 40. Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.
    Su WL, Chuang SC, Wang YC, Chen LA, Huang JW, Chang WT, Wang SN, Lee KT, Lin CS, Kuo KK.
    Cancer Biomark; 2020 Aug 17; 28(3):341-350. PubMed ID: 32390596
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.